Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesWound CareCommunity Health Plan Washington CTP Coverage Upda…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedCommunity Health Plan WashingtonPolicy MC.CP.MP.185

    Skin and Soft Tissue Substitutes (Cellular and Tissue‑Based Products)

    Customize your policy alerts

    Sign up for Community Health Plan Washington Policy MC.CP.MP.185 alerts

    Get alerted when Policy MC.CP.MP.185 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, coverage criteria, documentation, product lists, coding guidance, and prior authorization requirements for cellular and tissue‑based products (CTPs) used to treat wounds including DFU, VLU, burns, breast reconstruction, DEB, and post‑reconstructive abdominal wounds for Medicare and affiliated plans.

    Policy Summary
    PayerCommunity Health Plan Washington
    PolicySkin and Soft Tissue Substitutes (CTPs) — coverage criteria for DFU, VLU, burns, reconstruction, DEB
    Policy CodePolicy MC.CP.MP.185
    Change TypeMaterial revision — added indicationsreorganized HCPCS tablesdefined initial up to 4 applications
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization documenting the specific wound, ≥4 weeks of prior conservative care, circulation and infection status, and the product HCPCS/Q-code to justify initial or continued CTP applications.
    SourceLink
    POLICY UPDATE CHANGES

    Added 'up to four initial applications of' to policy statement I.

    Replaced original HCPCS table structure: new DFU-specific and VLU-specific HCPCS tables and multiple HCPCS code additions/changes.

    Added criteria sections for burns, breast reconstruction, dystrophic epidermolysis bullosa, and post‑reconstructive abdominal wall wounds.

    Specified that policy statements I. and III. apply to DFU and VLU and replaced 'skin substitute' wording with 'skin and soft tissue substitute/CTP'.

    Moved HCPCS codes A2009 and Q4304 from list that do NOT support medical necessity to list that DO support medical necessity.

    4
    initial authorized applications
    up to 8total applications (per 12‑week episode)
    ≥4 wksminimum conservative care duration
    ABI ≥0.6 / toe >30circulation threshold
    no infectionrequired wound status
    100+HCPCS entries listed

    Coverage Criteria and Indications

    Initial Therapy (DFU and VLU)

    Covered when ALL of the following are met:

    Initial applications (up to four) for DFU and VLU: A. Request indicates the specific wound to which the skin substitute/CTP will be applied; B. Wound is chronic (failed to respond to ≥4 weeks of standard wound treatment as part of organized conservative therapy); C. Wound characteristics and treatment plan are documented; D. Standard wound care has failed, including appropriate measures (debridement, dressings, off‑loading/compression as appropriate) and wound area reduced by <50% in four weeks; E. Documentation of effort to cease nicotine use for at least four weeks during conservative care or no nicotine use; F. Wound characteristics: partial‑ or full‑thickness ulcer with clean granular base; no involvement of tendon, muscle, joint capsule, or exposed bone or sinus tract (unless Integra per FDA); no wound infection; clean and free of necrotic debris or exudate; G. Adequate circulation demonstrated (e.g., ABI ≥ 0.6 or toe pressure > 30 mmHg); H. For DFU: diagnosis of diabetes (Type 1 or 2) with medical management, documented ≥4 weeks conservative care, no osteomyelitis/nidus of infection, and requested product is one of the products listed in the policy tables for DFU; For VLU: chronic non‑infected venous leg ulcer failed ≥4 weeks conservative care with documented compliance and appropriate venous assessment; I. Requested use complies with FDA‑approved indications for the specific product; J. Only one skin substitute/CTP will be simultaneously in place per wound episode (product change within episode allowed under application limits); K. Graft applied in a single layer without overlay and in compliance with product label/application technique; L. Documentation requirements met for each application (baseline and follow‑up wound photos/measurements; procedure note with product name/label or NDC and size; amount used/wasted and lot information; rationale for size selection to minimize wastage); M. No contraindications (e.g., uncontrolled underlying conditions, active infection, continued tobacco smoking without physician attempt to effect cessation, known hypersensitivity to product components, or partial‑thickness loss with retention of epithelial appendages).up to 4 applications

    See product lists and HCPCS tables in the policy for allowable products and codes.

    Continuation Therapy

    Covered when ALL of the following are met:

    Continuation/extended therapy (beyond initial up to 4, to a total ≤8 applications): A. Request indicates the specific wound and is for one of the listed products for DFU or VLU; B. Use complies with labeled indications for the product; C. Documentation explains medical necessity for additional applications or extended time, showing that initial applications resulted in wound improvement and there is reasonable expectation of continued healing; D. Documentation includes estimated additional number of applications/timeframe, contingency plan if no continued improvement, and documentation that modifiable risk factors are being addressed (including venous management for VLU); E. Per‑application documentation maintained: procedure description with product name/NDC/size, wound photos/measurements baseline and follow‑up, single‑layer application per label, and justification of size to minimize wastage; F. Only one skin substitute/CTP simultaneously per wound episode; G. When portion discarded, medical record documents amount administered and wasted with date/time and reason; H. Treatment course does not exceed policy limits (total applications not to exceed eight per wound per 12‑week episode).total ≤8 applications per wound per 12‑week episode

    Initial authorization up to four applications; continuation requires demonstration of benefit and documentation as above.

    Not Medically Necessary (DFU/VLU)

    Not medically necessary in the following explicit scenarios:

    Not medically necessary (DFU/VLU): A. Partial‑thickness loss with retention of epithelial appendages (epithelium will repopulate); B. Simultaneous use of more than one skin substitute/CTP for the same wound episode; C. Repeat or alternative applications after a previous full course was unsuccessful (unsuccessful defined as increased size/depth or no change and no sign of improvement for four weeks past start of therapy); D. Retreatment of healed ulcers (greater than 75% size reduction and <0.5 cm²); E. Re‑treatment within one year of any given course for a venous stasis ulcer or diabetic foot ulcer; F. Treatment courses extending beyond twelve weeks without justification (typically treatment will not exceed 12 weeks).

    These scenarios are explicit exclusions for DFU and VLU per policy.

    Burns (Non‑Medicare plan criteria)

    Covered when ALL of the following are met:

    Burns - non‑Medicare plan criteria: A. Request indicates the specific burn wound to which the skin substitute/CTP will be applied; B. Sufficient autograft is not available at time of excision or autograft is not feasible due to the member's physiologic condition; C. No evidence of burn wound infection; D. Burn is deep partial‑thickness or full‑thickness; E. Documentation that modifiable risk factors for impaired healing are being addressed (including review of glucose/HbA1c if indicated, nutrition/activity, medication history, and smoking status/counseling); F. Treatment uses an appropriate listed allograft, xenograft, or tissue‑engineered product (e.g., Biobrane, TransCyte, Integra variants, Suprathel, Epicel HDE where applicable); G. Only one CTP in place per wound episode; H. Graft applied in single layer per label/application technique; I. Documentation requirements met for each application (photos, procedure details, amount used/wasted and lot information).

    Applies to non‑Medicare plans per policy section IV; see HCPCS table entries for product‑level coverage.

    Breast Reconstruction

    Covered when ALL of the following are met:

    Breast reconstruction (non‑Medicare plans): A. Request indicates the specific wound to which the skin substitute/CTP will be applied; B. Use is for post‑mastectomy breast reconstruction; C. No evidence of wound infection; D. Documentation that modifiable risk factors are addressed (review of glucose/HbA1c if indicated, nutrition/activity, medication history) and smoking status documented with counseling/enrollment in cessation if applicable; E. Treatment with a listed product indicated for reconstruction (e.g., AlloDerm, Cortiva, DermACELL, FlexHD/AllopatchHD); F. Only one CTP simultaneously per wound episode; G. Graft applied in single layer per label; H. Per‑application documentation requirements met (photos, procedure note with product/NDC/size, amount used/wasted).

    Applies to non‑Medicare plans per policy section V; coding and product lists in HCPCS tables identify covered products.

    DEB (OrCel HDE)

    Covered when ALL of the following are met:

    OrCel (HDE) for dystrophic epidermolysis bullosa (DEB): A. Request indicates the specific wound to which OrCel will be applied (mitten hand deformity due to dystrophic EB); B. Use is according to the U.S. FDA Humanitarian Device Exemption (HDE) labeling for OrCel; C. No evidence of wound infection; D. Documentation that modifiable risk factors are addressed (review of glucose/HbA1c if indicated, nutrition/activity, medication history) and smoking status addressed (non‑smoker or completed/enrolled in cessation therapy); E. Only one skin and soft tissue substitute/CTP will be simultaneously in place per wound episode; F. Per‑application documentation requirements met.

    This section reflects OrCel HDE coverage for mitten hand deformities due to dystrophic DEB (policy section VI).

    Covered indications with required criteria

    Medically necessary when ALL of the following are met for the specific wound:

    General required conditions for covered indications: A. Request indicates the specific wound; B. No evidence of wound infection; C. Modifiable risk factors for impaired healing are being addressed; D. Review of current blood glucose/HbA1c if history of prediabetes/diabetes; E. Diet, nutrition, and activity reviewed; F. Updated medication history and relevant comorbidities documented; G. Patient is a non‑smoker OR has been counseled and completed/is enrolled in smoking cessation therapy; H. Per‑application documentation requirements met (graphic evidence of size/depth, procedure note with product/NDC/size, amount used/wasted and lot information).

    Applies across multiple covered indications (e.g., OrCel HDE, post‑abdominal reconstruction, burns, breast reconstruction).

    Product‑specific acceptable treatments: Treatment with specified skin and soft tissue substitutes/CTPs listed for the indication (for example: AlloDerm, Phasix ST, Strattice, FlexHD/AllopatchHD, DermACELL, Cortiva, Integra variants, Biobrane, TransCyte, Suprathel, Epicel HDE, etc.).

    Only products listed in the HCPCS/CTP tables as medically necessary for the respective indication are covered.

    Application constraints: Only one skin and soft tissue substitute/CTP may be in place simultaneously per wound episode; graft applied in single layer without overlay, in compliance with label application techniques; first application begins the episode of care and application limits (initial up to four, total up to eight per 12‑week episode for DFU/VLU) apply where specified.

    OrCel for dystrophic epidermolysis bullosa (HDE)

    OrCel (HDE) specific criteria for mitten hand deformities due to dystrophic EB when ALL of the following are met:

    OrCel HDE specific requirements: A. Request indicates the specific wound (mitten hand deformity due to dystrophic EB); B. Use according to FDA HDE labeling for OrCel; C. No evidence of wound infection; D. Documentation that modifiable risk factors are being addressed and review of glucose/HbA1c if indicated; E. Diet/nutrition/activity and updated medication history reviewed; F. Patient is non‑smoker or has completed/is enrolled in smoking cessation counseling; G. Only one skin substitute/CTP simultaneously per wound episode; H. Per‑application documentation requirements met.

    OrCel is covered under the HDE for this specific DEB indication when these conditions are met.

    Post-reconstruction abdominal wall wounds

    Covered when ALL of the following are met:

    Post‑reconstruction abdominal wall wounds: A. Request indicates the specific wound to which the skin substitute/CTP will be applied; B. Use is for repair of hernias or complex abdominal wall surgical repair; C. No evidence of wound infection; D. Documentation that modifiable risk factors are addressed (including review of glucose/HbA1c if indicated, nutrition/activity, updated medication history); E. Patient is non‑smoker or has completed/is enrolled in smoking cessation therapy; F. Treatment with specified products listed for this indication (e.g., AlloDerm Q4116, Phasix ST C1781, Strattice Q4130); G. Only one skin substitute/CTP in place per wound episode; H. Graft applied single layer per label and per‑application documentation requirements met.

    Applies to non‑Medicare plans per policy section VII and references HCPCS codes for product‑level coverage.

    General coding-to-product matching requirement

    Coverage is supported when product, application, and coding align with medical necessity:

    Coding and product match: A. The selected skin substitute product must be billed with the HCPCS/CPT codes that correspond to the application size and body site as listed in the policy code tables (CPT codes 15271–15278 and HCPCS application codes G0681–G0684; HCPCS product codes listed in Tables 2–4); B. Products marked with an asterisk in the HCPCS tables must be specified on the claim as noted; C. Wound surface area thresholds for CPT/HCPCS billing must be observed (first 25 sq cm and additional 25 sq cm increments or first 100 sq cm and additional 100 sq cm increments as applicable); D. Use of codes that are listed in the policy as not supporting medical necessity (HCPCS Table 3 entries) will not support coverage absent meeting the medical necessity criteria and product listing in a supporting table.see code thresholds

    Refer to the policy HCPCS/CPT tables for the exact code‑to‑product mapping and application size thresholds.

    High-level coverage structure (DFU/VLU and additional indications)

    Covered when ALL of the following are met (high‑level):

    Initial approval and application limits: Up to four initial applications are authorized for DFU and VLU when product type and clinical criteria in the policy are met; continuation to a total of up to eight applications per wound per 12‑week episode requires documentation of benefit and the continuation criteria; the first application begins the episode of care.up to 4 initial; total ≤8 per 12‑week episode

    Operationalizes initial approval quantity and staged approval approach added in the revision history.

    Additional indication sections added: Policy includes new distinct sections for burns, breast reconstruction, dystrophic epidermolysis bullosa (OrCel HDE), and post‑reconstructive abdominal wall wounds with indication‑specific criteria.

    See sections IV–VII for full indication‑specific criteria and product lists.

    Coding concordance and table updates: Use HCPCS codes from the policy tables that support medical necessity for the specific indication (DFU, VLU, other). Note that some codes were reorganized between supporting and non‑supporting lists during the revisions (e.g., A2009 and Q4304 noted as moved), so refer to the current tables when preparing claims.

    The policy explicitly prohibits simultaneous placement of more than one skin and soft tissue substitute/CTP for the same wound episode and excludes repeat or alternative applications when a prior full course was unsuccessful. An "unsuccessful" course is defined as an increase in size or depth of the ulcer, or no change from baseline with no sign of improvement for a period of four weeks after the start of therapy. When a single‑use package is partially discarded, documentation must support the amount applied and the portion discarded; payment may be made for the discarded portion up to the package amount. All documentation for each application must be maintained in the member’s medical record and made available upon request.

    Use of skin and soft tissue substitutes/CTPs for indications not listed in sections I–VII is considered not medically necessary for non‑Medicare plans. The policy specifically names pressure ulcers and other off‑label or non‑listed uses as examples of exclusions. Additionally, repeat applications after an initial treatment course that is unsuccessful for four weeks, and treatment that extends beyond specified duration limits (see policy) are listed among scenarios that will not support medical necessity.

    The policy includes a dedicated HCPCS Code Table 3 that lists codes which do not support medical necessity for any indication. Examples from that table include codes such as A2001, A2002, A2004 and multiple other A‑series/Q‑series entries. The table is intended to guide billing and claims submission: codes appearing in HCPCS Code Table 3 should not be used to justify coverage under the medical necessity criteria in this policy.

    Sections VIII and IX were added to the policy to enumerate uses considered not medically necessary and indications for which current evidence does not support use of skin and soft tissue substitutes/CTPs. These sections provide the formal list of exclusions and products or indications lacking evidence (e.g., pressure ulcers and any product not listed as medically necessary for the respective indications). Refer to those sections for the full exclusions and examples.

    The policy references applicable CMS local coverage determinations and a local coverage article regarding wound application of CTPs. When evaluating cosmetic or reconstructive surgery uses, providers should consult the referenced LCDs/LCAs (for example, L36690, L35041, L36377 and A56696) because coverage for cosmetic or reconstructive indications may be governed by those CMS determinations in addition to plan rules.

    Coverage decisions under this clinical policy are subject to each member’s plan terms, conditions, exclusions and limitations. For Medicaid members, state Medicaid coverage provisions take precedence when they conflict with this policy. The Health Plan retains the right to change or withdraw this clinical policy and providers should confirm applicable contractual and regulatory requirements prior to relying on the policy for coverage determinations.

    The policy clarifies that products are intended for treatment of wounds with appropriate depth (full thickness or partial thickness without retention of epithelial appendages) and that a single skin substitute/CTP may be used per wound episode. Partial‑thickness wounds that retain epithelial appendages are explicitly not appropriate for CTPs. Repeat or alternative treatments after a prior full course that did not demonstrate improvement within four weeks are excluded. These constraints are in place to ensure CTPs are reserved for wounds that have truly failed adequate conservative care and where a single, properly selected product is applied according to label instructions.

    Treatment beyond twelve weeks is considered not medically necessary for the non‑Medicare plan indications described in this policy. In addition, repeat applications after an initial treatment is unsuccessful for a period of four weeks from the start of therapy will not support continued coverage. These timeframes are used to identify failure of therapy and to limit indefinite or unsupported retreatment.

    Products enumerated in HCPCS Code Table 3 are identified in the policy as not supporting medical necessity for the indications covered by this document. That table should be used as the reference when determining whether a listed HCPCS code/product is eligible to support a claim under the medical necessity criteria.

    The updated policy explicitly added sections that list indications deemed not medically necessary and those not supported by current evidence. These added sections formalize exclusions (for example, pressure ulcers and other non‑listed indications) and clarify that products not listed as medically necessary for a given indication are not supported by the policy.

    Common denial scenarios referenced in this policy include: CTP use for partial‑thickness wounds that retain epithelial appendages; simultaneous use of more than one product for the same wound episode; repeat or alternative applications after a prior full course was unsuccessful (no improvement within four weeks); retreatment of healed ulcers; requests for treatment beyond twelve weeks (non‑Medicare plans); and repeat applications after unsuccessful initial treatment beyond four weeks. These scenarios are highlighted because they frequently lead to coverage denials and are mirrored in the provider documentation and prior authorization requirements.

    Coding, HCPCS and CPT Tables

    Listed HCPCS/Q/accelerated codes for CTPs and graft productsHCPCS
    Q4151AmnioBand, guardian
    Q4159Affinity
    Q4101Apligraf
    Q4122DermACELL, DermACELL AWM, DermACELL AWM porous
    Q4203Derma-Gide
    Q4431Dermagraft
    Q4187Epicord
    Q4186Epifix
    Q4128FlexHD or AllopatchHD
    Q4133Grafix PRIME, GrafixPL PRIME, Stravix and StravixPL
    1–10 of 28
    1/3
    Covered HCPCS/Q/Codes for listed productsHCPCSCovered
    Q4116AlloDerm
    Q4433Cortiva
    Q4122DermaCell
    Q4128FlexHD or AllopatchHD
    Q4130Strattice
    C1781Phasix ST
    Covered CPT Codes (procedure codes supporting medical necessity criteria)CPTCovered
    15271Application of skin substitute graft to trunk, arms, legs, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area.
    15272Application of skin substitute graft to trunk, arms, legs, total wound surface area up to 100 sq cm; each additional 25 sq cm wound surface area, or part thereof.
    15273Application of skin substitute graft to trunk, arms, legs, total wound surface area greater than or equal to 100 sq cm; first 100 sq cm wound surface area, or 1% of body area of infants and children.
    15274Application of skin substitute graft to trunk, arms, legs, total wound surface area greater than or equal to 100 sq cm; each additional 100 sq cm wound surface area, or part thereof.
    15275Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area.
    15276Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; each additional 25 sq cm wound surface area.
    15277Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area greater than or equal to 100 sq cm; first 100 sq cm wound surface area, or 1% of body area of infants and children.
    15278Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area greater than or equal to 100 sq cm; each additional 100 sq cm wound surface area, or part thereof.
    Covered HCPCS Application CodesHCPCSCovered
    G0681Application of a PMA, 510(k), 361 HCT/P nonsheet form skin substitute for a wound surface area up to 100 sq cm; first 25 sq cm or less.
    G0682Application of a PMA, 510(k), 361 HCT/P nonsheet form skin substitute for a wound surface area up to 100 sq cm; each additional 25 sq cm.
    G0683Application of a PMA, 510(k), 361 HCT/P nonsheet form skin substitute graft for wound surface greater than or equal to 100 sq cm; first 100 sq cm.
    G0684Application of a PMA, 510(k), 361 HCT/P nonsheet form skin substitute graft for wound surface greater than or equal to 100 sq cm; each additional 100 sq cm.
    HCPCS/Q-code Product List (supporting medical necessity criteria)HCPCSCovered
    A2012SUPRATHEL, per sq cm.
    A2019Kerecis Omega3 MariGen Shield, per sq cm.
    A2043BIOBRANE, per sq cm.
    A2044BIOBRANE Glove, each.
    A4100*Nonsheet form skin substitute, FDA-cleared as a device, not otherwise specified [OrCel].
    C1781*Mesh (implantable) [Phasix ST or Alloderm].
    C9363Skin substitute (Integra Meshed Bilayer Wound Matrix), per sq cm.
    C9399*Unclassified drugs or biologicals [Epicel].
    Q4101Apligraf, per sq cm.
    Q4102Oasis wound matrix, per sq cm.
    1–10 of 31
    1/4
    HCPCS/Q-codes that do NOT support medical necessity criteriaHCPCSNot Covered
    A2001InnovaMatrix AC, per sq cm.
    A2002Mirragen Advanced Wound Matrix, per sq cm.
    A2004XCelliStem, 1 mg.
    A2005Microlyte Matrix, per sq cm.
    A2006NovoSorb SynPath dermal matrix, per sq cm.
    A2007Restrata, per sq cm.
    A2008TheraGenesis, per sq cm.
    C8002Preparation of skin cell suspension autograft, automated, including all enzymatic processing and device components.
    HCPCS codes listed in document chunks 54–62HCPCS
    Q4248Dermacyte Amniotic Membrane Allograft, per sq cm.
    Q4249AMNIPLY, for topical use only, per sq cm.
    Q4250AmnioAmp-MP, per sq cm.
    Q4251Vim, per sq cm.
    Q4252Vendaje, per sq cm.
    Q4253Zenith Amniotic Membrane, per sq cm.
    Q4254Novafix DL, per sq cm.
    Q4255REGUaRD, for topical use only, per sq cm.
    Q4256MLG-Complete, per sq cm.
    Q4257Relese, per sq cm.
    1–10 of 182
    1/19
    Additional HCPCS and CPT codes referenced as added/organized in coding tablesHCPCS
    A2001
    A2002
    A2004
    A2005
    A2008
    A2009
    A2012
    A2020
    A2021
    A2022
    1–10 of 99
    1/10
    Referenced CMS LCD/LCAsmixed
    L36690Local coverage determination: wound application of cellular and/or tissue based products (CTPs), lower extremities
    L35041Local coverage determination: application of bioengineered skin substitutes to lower extremity chronic non-healing wounds
    L36377Local coverage determination: application of skin substitute grafts for treatment of DFU and VLU of lower extremities
    A56696Local coverage article: Billing and coding: wound application of cellular and/or tissue based products (CTPs), lower extremities
    Ankle‑Brachial Index (ABI) threshold
    Ankle-Brachial Index (ABI)ABI no less than 0.6
    Evidence methodMeasured by physical examination or documented ABI testing
    ContextRequired to demonstrate adequate circulation/oxygenation to support tissue growth/wound healing
    Toe pressure threshold
    Toe pressure threshold> 30 mmHg

    What Providers Must Do

    Prior Authorization

    Prior authorization required — document wound, ≥4 weeks conservative care, wound characteristics

    Prior authorization is required for listed cellular and tissue-based products (CTPs) for DFU and VLU. Requests must identify the specific wound, document at least four weeks of prior conservative wound care, describe wound characteristics and treatment plan, confirm absence of contraindications, and specify the requested product/HCPCS/Q-code and justification for initial or continued applications.

    • Request must indicate the specific wound to which the CTP will be applied (chunk 5).
    • Documented ≥4 weeks of standard conservative therapy and failure (wound area reduced by <50% in 4 weeks) (chunk 5).
    • Include product identification (HCPCS/Q-code, package label or NDC) and justification for initial or continued applications (chunks 8, 11).
    Prior Authorization

    Prior authorization — document no infection and risk‑factor optimization (smoking cessation)

    Prior authorization requests for listed products and indications must document absence of wound infection and that modifiable risk factors have been addressed (including smoking cessation counseling or completion where applicable), and must specify the selected product from the listed HCPCS/Q-codes.

    Clinical Background and Evidence Summary

    Standard treatment for chronic lower extremity ulcers includes infection control, edema management, off‑loading or appropriate compression (for venous disease), sharp debridement when indicated, and management of comorbidities such as diabetes and nutritional status. CTPs are considered when wounds have failed adequate conservative therapy and patient/wound factors (including circulation and absence of infection) support the likelihood of healing.

    Definitions and Terminology

    Chronic wound — definition
    Chronic wound definitionA wound that does not respond to at least four weeks of standard wound treatment as part of organized, comprehensive conservative therapy.
    Clinical featuresChronic wounds fail to progress toward granulation/epithelialization and may increase in size or depth without indication of improvement.
    Role in coverageWound must be documented as chronic to meet initial therapy criteria for CTP use.
    Failed response — definition
    Failed response definitionAn ulcer that has failed to respond to documented appropriate wound‑care measures, has increased in size or depth, or has not changed in baseline size or depth and shows no indication that improvement is likely.
    Use in criteria

    Policy Changes and Revision Notes

    2024-12-25coding_reorganization

    Coding tables were reorganized: DFU-specific Table 2 and VLU-specific Table 3 created, original Table 3 renumbered to Table 4, and many HCPCS codes were added or moved between tables.

    2025-03-26new_indications_added

    Added new criteria sections for burns (IV), breast reconstruction (V), dystrophic epidermolysis bullosa (VI), and post-reconstructive abdominal wall wounds (VII); expanded background and updated criteria sources.

    2025-10-25scope_and_terminology_clarified
    Policy Summary
    PayerCommunity Health Plan Washington
    PolicySkin and Soft Tissue Substitutes (CTPs) — coverage criteria for DFU, VLU, burns, reconstruction, DEB
    Policy CodePolicy MC.CP.MP.185
    Change TypeMaterial revision — added indicationsreorganized HCPCS tablesdefined initial up to 4 applications
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization documenting the specific wound, ≥4 weeks of prior conservative care, circulation and infection status, and the product HCPCS/Q-code to justify initial or continued CTP applications.
    SourceLink
    On This Page
    Coverage Criteria and IndicationsCoding, HCPCS and CPT TablesWhat Providers Must DoClinical Background and Evidence SummaryDefinitions and TerminologyPolicy Changes and Revision Notes

    Product‑and code‑specific limits are set in the HCPCS/CPT tables.

    Coding tables were reorganized and expanded in the recent revision.

    Evidence methodDocumented toe pressure measurement in mmHg
    ContextUsed as alternative circulation evidence when ABI not available or unreliable
    Conservative wound care duration before CTP
    Minimum conservative therapy duration≥ 4 weeks of organized, comprehensive conservative wound care
    Components expectedDebridement, standard dressings, compression/off‑loading as appropriate
    Documentation neededRecord of ≥4 weeks conservative care must be in the chart prior to CTP request
    Wound area reduction threshold
    Wound area reduction thresholdWound area reduced by <50% over four weeks
    Use in decision-makingFailure to reduce by ≥50% in 4 weeks supports need for CTP
    DocumentationSerial wound measurements/photos demonstrating <50% reduction in 4 weeks
    Maximum treatment duration
    Maximum treatment durationTreatment longer than 12 weeks is considered not medically necessary
    Repeat application timingRepeat applications after unsuccessful initial treatment beyond 4 weeks are not supported
    Non‑Medicare noteNon‑Medicare plans explicitly list treatment >12 weeks as not medically necessary (Section VIII.A)
    Wound surface area billing thresholds
    Billing split — small incrementsCPT/HCPCS codes split by wound surface area: first 25 sq cm, each additional 25 sq cm (codes 15271/15272; G0681/G0682)
    Billing split — large areasCodes for total wound area ≥100 sq cm use first 100 sq cm and each additional 100 sq cm (15273/15274; G0683/G0684)
    Pediatric/infill ruleFor infants/children, 1% body area may be used instead of 100 sq cm per code descriptors
    Initial applications (operational limits)
    Initial application limitUp to 4 initial applications are approved for DFU and VLU when criteria met
    Episode startThe first application begins the episode of care; only one CTP may be in place per wound episode
    Per-application documentationEach initial application requires photo/measurement documentation, product/NDC and size, and wastage record if applicable
    Total applications allowed
    Total applications allowedUp to a total of 8 applications per wound (initial up to 4, continuation to total ≤8) within the treatment episode
    Continuation requirementsExtended applications require documentation that initial applications resulted in healing and justify additional applications
    Payment for discarded productIf a single‑use package is partially discarded, payment may be made for portion discarded plus amount applied up to package amount (documented)
    • No evidence of wound infection required for covered indications (chunks 18, 21).
    • Documentation that modifiable risk factors are being addressed and smoking cessation counseling/completion when applicable (chunks 18, 21).
    • Product requested must be one of the listed HCPCS/Q-codes for the indication (chunk 18).
    Prior Authorization

    Specify product for annotated HCPCS entries — may require prior authorization

    Certain HCPCS entries in the policy tables are annotated with an asterisk and require that the provider specify the exact product on the claim or authorization; product-specified entries may trigger prior authorization or require product identification to support medical necessity.

    • Products marked with an asterisk must be specified as noted in the HCPCS table (chunk 46).
    • Examples include annotated entries such as A4100*, C1781*, Q4431*, Q4433* that require product specification (chunks 45–46).
    Prior Authorization

    Prior authorization — initial up to 4 applications; continuation up to total 8

    Prior authorization decisions follow the staged approval limits in the policy: up to four initial applications are authorized, with continuation requests considered up to a total of eight applications per wound within a 12-week episode when continuation criteria are met.

    • Initial approval: up to four applications for DFU and VLU when criteria are met (chunk 5).
    • Continuation: requests beyond initial four considered up to total of eight applications per 12-week episode with documentation of response and medical necessity (chunks 9, 66).
    Prior Authorization

    Prior authorization — consult applicable CMS LCDs and articles

    Consult applicable CMS local coverage determinations (LCDs) referenced by the policy when making authorization decisions; the policy cites LCDs and a Local Coverage Article that inform coverage rules and coding guidance.

    • Referenced LCDs include L36690, L35041, L36377 and Local Coverage Article A56696 (chunk 72).
    • For Medicare members, review applicable NCDs/LCDs and Medicare Coverage Articles prior to applying policy criteria (chunk 97).
    Prior Authorization

    Check NCDs/LCDs and plan coverage documents before authorizing

    Before authorizing CTPs for Medicare members, review all applicable Medicare NCDs, LCDs, and plan coverage documents; adherence with CMS determinations may be required for coverage.

    • Note to review Medicare NCDs/LCDs for consistency with this clinical policy prior to applying criteria (chunk 97).
    • CMS references cited in the policy should be checked for updates (chunk 72).
    Step Therapy

    Document wound preparation prior to CTP — use preparation code at least once

    Authorization should confirm that appropriate wound preparation was performed and coded at least once prior to CTP placement; repeat billing for surgical preparation services with skin substitute application codes is not considered reasonable and necessary.

    • Each wound is expected to have at least one appropriate wound preparation code used at initiation of care prior to placement of the skin substitute graft (chunk 13).
    • Repeat use of surgical preparation services in conjunction with skin substitute application codes is considered not reasonable and necessary (chunk 13).
    Step Therapy

    Confirm standard wound care applied and documented before CTP

    Ensure standard wound care measures were applied and documented before CTP use: infection control, debridement, offloading/compression, edema management, and systemic disease management must have been attempted and documented.

    • Policy requires demonstration that standard wound-care measures including debridement, standard dressings, compression, and off‑loading were used (chunk 5).
    • Background highlights infection control, edema management, offloading/compression, debridement, and systemic disease management as standard care prior to CTPs (chunk 25).
    Note
    Step Therapy

    Staged approval — initial up to 4, continuation to total up to 8 with justification

    Staged application approvals: initial authorization typically covers up to four applications; continuation requests must document clinical response and justification to support approval up to a total of eight applications within a 12-week episode.

    • Initial approved quantity: up to four applications (chunk 66).
    • Continuation up to a total of eight applications per 12-week episode requires documentation of response to initial applications and rationale for further applications (chunk 9).
    Note
    Note
    Documentation Required

    Required documentation per application — photos, measurements, procedure note, product name/label/NDC, wastage details

    For each application, maintain comprehensive documentation in the medical record: baseline and follow-up wound photos/measurements, complete procedure description including product name/label or NDC and size, amount used and amount wasted with date/time/reason, and manufacturer lot/serial information.

    • Graphic evidence of wound size, depth, and characteristics at baseline and follow-up with measurements (chunks 8, 11).
    • Complete procedure description including product used with package label or NDC and size (chunks 8, 11).
    • Document amount administered and wasted, date/time and reason for wastage, and manufacturer lot/serial/batch identification when available (chunks 8, 13).
    • All documentation must be maintained in the member's medical record and made available upon request (chunks 8, 12).
    Documentation Required

    Per-application baseline and follow-up photos plus full procedure documentation

    Document baseline and follow-up graphic/photo evidence and full procedure documentation for every application, including rationale for chosen product size to minimize wastage and evidence that criteria for continued therapy are met.

    • Graphic evidence and measurements at baseline and follow-up (chunk 20).
    • Procedure note must include product NDC/label, size, and rationale for chosen size to minimize wastage (chunk 22).
    • Continuation requests must explain how initial treatment resulted in healing progress and why additional applications are medically necessary (chunk 9).
    Billing Rule

    Record retention and billing for discarded single‑use product — document amount wasted and retained

    Maintain records of product use and wastage; when a single-use package is partially discarded, document amount applied and wasted and, where applicable, payment may be made for the discarded portion up to the package amount.

    • Document amount administered and wasted, date/time and reason for wastage, and manufacturer lot number (chunks 12, 13).
    • Payment may be made for portion discarded along with amount applied up to product package amount (chunks 12, 19).
    • All records must be maintained in the medical record and provided upon request (chunks 12, 19).
    Billing Rule

    Use current coding sources and specify product when required (*)

    Use current CPT and HCPCS coding sources when submitting authorizations and claims; include product specification when the HCPCS/Q-code table notes that the product must be specified (products marked with an asterisk).

    • Codes in the policy are informational; providers must reference up-to-date CPT/HCPCS manuals prior to claim submission (chunk 39).
    • Products marked with an asterisk in HCPCS tables must be specified to support medical necessity (chunk 46).
    Documentation Required

    Supply required documentation and product lists as requested under criteria II

    Comply with the policy's documentation requirements referenced under the coverage criteria; providers may be asked to supply product lists for DFU and VLU and must maintain required records to support medical necessity.

    • Policy includes documentation requirements under criteria II and may request product lists for DFU and VLU (chunk 63).
    • Providers must supply the documentation specified in the policy for each application (chunk 66).
    Documentation Required

    Follow CMS LCDs and local billing/coding guidance when documenting and coding

    Follow CMS LCDs and billing guidance cited in the policy for documentation and coding; authorization and claims should align with the referenced LCDs and local billing articles.

    • Documentation and coding should follow the cited CMS LCDs and the Local Coverage Article A56696 (chunk 72).
    • For Medicare patients, ensure consistency with relevant NCDs/LCDs prior to applying policy criteria (chunk 97).
    Documentation Required

    Document medical necessity and consider member contract/ regulatory terms

    Providers must document medical necessity, exercise professional judgment, and recognize that coverage determinations are also subject to member contract terms, state and federal rules, and Health Plan administrative policies.

    • Providers are expected to exercise professional medical judgment and document medical necessity (chunk 96).
    • Coverage decisions are subject to member contracts, state Medicaid provisions, and federal requirements (chunk 95).
    Denial Risk

    Common denial scenarios — partial‑thickness with appendages, simultaneous products, repeat/retreatment exclusions

    Common denial scenarios include use for partial‑thickness wounds with retention of epithelial appendages, simultaneous use of more than one product in an episode, repeat or alternative applications after an unsuccessful full course, retreatment of healed ulcers, and re-treatment within one year for VLU/DFU.

    • Partial thickness loss with retention of epithelial appendages is not medically necessary (chunk 12).
    • Simultaneous use of >1 product in a wound episode is not allowed (chunks 8, 11).
    • Repeat/alternative applications after an unsuccessful prior full course and retreatment of healed ulcers (>75% reduction and <0.5 cm2) are not medically necessary (chunk 12).
    • Re-treatment within one year for a given course in VLU or DFU is not medically necessary (chunk 12).
    Denial Risk

    Denial risk — requests >12 weeks or repeat applications after unsuccessful initial course

    Requests for treatment longer than twelve weeks or repeat applications after an initial treatment was unsuccessful for a period of four weeks past the start of therapy are considered not medically necessary and may be denied.

    • Treatment durations exceeding 12 weeks are considered not medically necessary (chunk 24).
    • Repeat applications after unsuccessful initial treatment (no improvement or worsening for 4 weeks past start of therapy) are not medically necessary (chunks 24, 9).
    Denial Risk

    Coding guidance is informational — incorrect or outdated coding risks denial

    Coding lists in the policy are informational and inclusion or exclusion of codes does not guarantee coverage; use of incorrect or outdated codes may result in claim denial.

    • Codes referenced in the clinical policy are for informational purposes only and inclusion/exclusion does not guarantee coverage (chunk 40).
    • Providers should reference current coding guidance prior to claim submission to avoid denial for incorrect coding (chunk 39).
    Denial Risk

    Risk of denial for coding/criteria mismatch — use listed HCPCS codes that match product and indication

    Use of HCPCS codes not listed in the policy tables that support medical necessity, or billing codes that do not match documented clinical criteria, may lead to noncoverage or denial; ensure coding aligns with the product and indication criteria.

    • The policy reorganized HCPCS tables; use codes from the tables that support medical necessity for the specific indication (chunk 66).
    • Failure to use HCPCS codes that correspond to the product/indication or mismatch between coding and clinical criteria may result in denial (chunks 65, 66).
    Denial Risk

    CMS LCD alignment required — check referenced LCDs/LCAs to avoid denial

    Authorization and billing that conflict with applicable CMS LCDs, NCDs, or cited billing articles may trigger denial; verify alignment with the referenced CMS determinations before authorizing or billing.

    • Use or billing that conflicts with applicable CMS local coverage determinations or billing/coding articles may trigger denial (chunks 72, 97).
    • Review the cited LCDs and Local Coverage Article to ensure authorization and claims align with CMS guidance (chunk 72).
    Denial Risk

    Denial risk — policy or contract exclusions and state/federal requirements may override coverage

    Coverage is governed by member coverage documents and state/federal requirements; services excluded by contract or by state/federal rules may be denied even if policy criteria are met.

    • Coverage decisions are subject to the terms, conditions, exclusions and limitations of the member's coverage documents and to state and federal requirements (chunk 95).
    • This clinical policy does not guarantee payment; the Health Plan may change, amend, or withdraw the policy (chunk 96).
    • For Medicare members, consistency with NCDs/LCDs should be ensured (chunk 97).
    Failed response is the trigger for considering CTPs after documented conservative care efforts.
    Measurement timeframeFailure is commonly assessed after a minimum of four weeks of appropriate conservative care.
    Cellular and tissue-based products (CTPs) — definition
    CTP definitionCellular and tissue‑based products (CTPs) are biologic covers composed of matrices, proteins, growth factors, or cellular components intended to stimulate or facilitate healing of full‑thickness skin loss; production varies by manufacturer and products are not equivalent to autologous skin.
    Scope of productsIncludes allografts, xenografts, bioengineered skin, tissue‑engineered products, and cultured epidermal autografts when applicable.
    Regulatory noteCTPs are regulated by FDA under different pathways depending on origin and composition; labeling and indications guide coverage decisions.
    Dystrophic Epidermolysis Bullosa (DEB) — definition
    DEB descriptionDystrophic Epidermolysis Bullosa (DEB) is an inherited disorder characterized by skin fragility and blistering that may lead to ulcerations and contractures.
    OrCel HDE noteOrCel has FDA Humanitarian Device Exemption (HDE) approval for mitten hand deformities due to recessive DEB as an adjunct to autograft procedures.
    Clinical implicationDEB‑related ulcers and contractures are a distinct indication with specific HDE coverage criteria in the policy.
    Reconstructive surgery (breast) — definition
    Reconstructive breast surgery definitionReconstructive surgery restores appearance and function of the breast after medically necessary mastectomy, other medical conditions, injury, or congenital abnormality.
    Policy contextBreast reconstruction using listed CTPs is covered under non‑Medicare criteria when documentation and infection/risk‑factor conditions are met.
    Application constraintsOnly one CTP per wound episode and single‑layer application per label are required for coverage.
    Dystrophic epidermolysis bullosa (DEB) — definition (duplicate)
    DEB (duplicate entry)Inherited disorder causing skin fragility and blistering; may lead to ulcerations and contractures; some devices (e.g., OrCel) have FDA HDE approval for specific DEB‑related use.
    Policy placementDEB criteria are included as a distinct section (OrCel HDE) in the policy for covered use in mitten hand deformities.
    Coverage noteOrCel use must comply with FDA HDE labeling and documentation requirements per the policy.
    skin and soft tissue substitute/CTP — terminology
    Terminology for productsThe policy uses the term 'skin and soft tissue substitute/CTP' throughout to refer to skin substitute products and cellular/tissue‑based products considered for wound care indications.
    Application constraintOnly one skin and soft tissue substitute/CTP will be simultaneously in place per wound episode; first application begins the episode of care.
    Application techniqueGraft must be applied in a single layer without overlay in compliance with label application techniques.
    Clinical policy — definition and scope
    Clinical policy definitionA clinical policy is a guide to medical necessity developed from current standards of practice, literature, government approvals, and expert opinion; it is not a payment guarantee or contract.
    Scope and useUsed to assist coverage decisions and benefit administration; decisions remain subject to plan terms, exclusions, legal/regulatory requirements.
    Evidence basisDeveloped from peer‑reviewed literature, guidelines, FDA approvals, and expert review as cited in the policy references.

    Specified that policy statements I and III apply to DFU and VLU and standardized terminology to 'skin and soft tissue substitute/CTP'; updated medically necessary product types for DFU and VLU and clarified application limits (up to four initial applications, up to a total of eight).

    2026-03-24operationalized_application_limitsLatest

    Added operational language 'up to four initial applications of' to policy statement I and documented initial/total application limits and related documentation notes.

    The policy cites multiple CMS local coverage determinations and a local coverage article as well as an extensive bibliographic reference list including randomized controlled trials and systematic assessments supporting clinical recommendations. Referenced CMS LCDs/LCAs and the bibliographic citations are provided in the policy reference section for clinical and billing guidance.